The imaging substudy is an afterthought in the protocol and the centrepiece of the debate
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
What is known and largely not known about skeletal outcomes during sustained weight loss.
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
The older-adult diet-and-exercise trials are the closest analogue to rapid pharmacological weight loss, and they are twenty years old.
The trials measured mass. Nobody measured whether the participants got weaker.
The recommendation survives scrutiny. The reasoning offered for it frequently does not.
The resistance-training and energy-deficit literature supports a higher protein intake. None of it was conducted in people taking an incretin.
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
What the Journal would want measured before treating this as settled in either direction.
Grading six widely repeated claims against the studies actually behind them.
Both the reassuring reading and the alarming reading are supportable from the same tables. This piece sets out which is which.
The trials measured mass. Nobody measured whether the participants got weaker.
A body-composition report gives four decimal places and no confidence interval. That is the whole difficulty in one sentence.
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
A substudy powered to describe a mean is not a substudy powered to detect a clinically meaningful individual change.
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
A survey of what the meta-analyses support, with the populations named.
A substudy powered to describe a mean is not a substudy powered to detect a clinically meaningful individual change.
Grading six widely repeated claims against the studies actually behind them.
What the Journal would want measured before treating this as settled in either direction.
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.